“On March 10, 2023, the FDA issued the Final Rule to Amend the MQSA Regulations. These updated requirements are to be implemented within 18 months after publication in the Federal Register. As noted in the final rule, the FDA concluded that 18 months was a practical timeframe for facilities to implement these requirements without undue hardship. Facilities are not precluded from including the required breast density notification prior to 18 months; however, facilities subject to MQSA must comply with all the requirements, including the breast density notification, no later than September 10, 2024.”
As a result of Insight’s forward-thinking and proactive development team’s efforts, OmniCare version 8 already contains all the necessary changes to fully comply with these final MQSA rules, including the updated density language required to be delivered in patient result letters.
OmniCare is a widely used for Breast Centers, Lung Cancer Screening, Incidental Imaging Findings, Patient Navigation, Pap Smears and more. For more information go to: www.insightmed.com, or call 800-643-0123.